JewishStatusOpen the app

Jewish News 24 · Aug 2, 2026

Jewish News 24 — photo status

🧠 Israeli-Developed Alzheimer's Therapy Shows Promising Early Results: An Israeli-developed antibody therapy, IBC-Ab002, showed a favorable safety profile in a Phase 1b trial of 40 early-stage Alzheimer's patients across Israel, the UK, and the Netherlands. Developed by ImmunoBrain based on research from the Weizmann Institute of Science, the treatment aims to restore the brain's natural immune-protective functions rather than target amyloid plaques. Published in Nature Medicine, the therapy was well tolerated and showed encouraging trends toward reducing biomarkers of neuronal damage, supporting further clinical development.

🧠 Israeli-Developed Alzheimer's Therapy Shows Promising Early Results: An Israeli-developed antibody therapy, IBC-Ab002, showed a favorable safety profile in a Phase 1b trial of 40 early-stage Alzheimer's patients across Israel, the UK, and the Netherlands. Developed by ImmunoBrain based on research from the Weizmann Institute of Science, the treatment aims to restore the brain's natural immune-protective functions rather than target amyloid plaques. Published in Nature Medicine, the therapy was well tolerated and showed encouraging trends toward reducing biomarkers of neuronal damage, supporting further clinical development.

Watch in the app All of Jewish News 24's statuses

More from Jewish News 24